Fiche publication
Date publication
avril 2025
Journal
Therapeutic advances in medical oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Dr AMARAL Teresa Maria
Tous les auteurs :
Reitmajer M, Nanz L, Müller N, Leiter U, Amaral T, Aebischer V, Flatz L, Forschner A
Lien Pubmed
Résumé
Talimogene laherparepvec (T-VEC) and interleukin-2 (IL-2) are both used in the intralesional treatment of melanoma skin metastases. T-VEC received regulatory approval from the European Medicines Agency and the U.S. Food and Drug Administration in 2015, while IL-2 has been used off-label for this purpose for many years. Despite their use in clinical practice, there is a lack of comparative data on the efficacy and safety of these treatments.
Mots clés
cutaneous metastases, interleukin 2 (IL-2), intralesional treatment, melanoma, overall survival (OS), progression-free survival (PFS), skin metastases, talimogene laherparepvec (T-VEC)
Référence
Ther Adv Med Oncol. 2025 04 1;17:17588359251324035
